Blood cancers represent the fourth most frequent cancer type in the developed world and account for 10% of yearly new cancer cases1.
In a complex and continuously evolving field, every assay can be a costly and time-consuming challenge. This may limit the productivity of specialists, thus potentially leading to delayed or inaccurate results.
Unravel the diversity of blood cancers
With an increasing comprehension of hematological malignancies, international recommendations have changed a lot over the past years. While lineages and clinical attributes remain the first determinants to characterize hematological malignancies, specialists are encouraged to include defining genetic abnormalities into subclassification of major tumor types2.
Lymphoid malignancies
Hematopoietic disruptions in the lymphocyte lineage can lead to:
- Lymphomas when abnormal lymphocytes accumulate in the lymphatic system;
- Acute lymphocytic leukemia (ALL) when immature lymphocytes accumulate rapidly in the blood and bone marrow, impairing other blood cell development;
- Chronic lymphocytic leukemia (CLL) when lymphocytes mature partly and accumulate progressively, impairing other blood cell development.
Myeloid malignancies
Hematopoietic disruptions in the myeloid lineage can lead to:
- Myelodysplastic syndromes (MDS) when too few functional blood cells are produced by the bone marrow;
- Myeloproliferative Neoplasms (MPN) when a clonal population proliferates in the bone marrow;
- Acute myeloid leukemia (AML) when immature white blood cells (granulocytes or monocytes) accumulate rapidly in the blood and bone marrow, impairing other blood cell development;
- Chronic myeloid leukemia (CML) when white blood cells mature partly and accumulate progressively, impairing other blood cell development.
Efficiently interpret and report relevant variants
Our solutions include direct access to the SOPHiA DDM™ Platform, a front-end application to upload and analyze genomic sample data. With its user-friendly interface and various cascading filters, users can generate personalized downloadable reports. It offers sufficient storage while keeping patient data safe by applying the highest industry standards of encryption in compliance with local data security policies.
Detection of SNVs, Indels, CNVs, and gene fusions
Comprehensive biomarker coverage
Customizable and scalable solutions
Streamlined workflow in 2 days
Rapid variant interpretation and reporting
Confidently detect valuable biomarkers
Save effort and time with our comprehensive, accurate, and future-proof end-to-end solutions. They allow the detection and characterization of complex genomic variants while adhering to the most up-to-date international guidelines.
Trusted analytical performance and advanced features of the SOPHiA DDM™ Platform enable the detection of even the most challenging variants thanks to our proprietary algorithms, PEPPER™, MUSKAT™ and MOKA™.
Streamline your workflow
Our genomic applications streamline the interpretation of complex genomic variants by combining a capture-based target enrichment kit with the analytical performance and advanced features of the SOPHiA DDM™ Platform.
Easy library preparation and capture kit
- Tailored probes for high on-target rate and coverage uniformity
- Ready-to-sequence in only 2 days
- Optimized multiplexing for a cost-effective process
- Compatible with various sequencers
Advanced analysis with SOPHiA DDM™️ Platform
- SNVs, Indels and CNVs detection, annotation and classification
- Easy visualization, filtering and reporting
- Secure storage of anonymized data
- Access to the latest scientific evidence on relevant alterations and to one of the largest networks of connected healthcare institutions
Discover the solutions of SOPHiA DDM™ for Blood Cancers
Our portfolio offers competitive advantages that can positively impact the study of blood cancers. It comprises a range of ready-to-use solutions, expertly designed to target relevant DNA variants and RNA fusion genes.
SOPHiA DDM™ for Myeloid Malignancies
Expand the scope of myeloid neoplasms management by targeting relevant DNA variants and RNA gene fusions.
SOPHiA DDM™ for Lymphoid Malignancies
Characterize key biomarkers with our comprehensive research applications developed by experts of the field.
SOPHiA DDM™ for MRD
Enhance MRD detection by combining NGS power and SOPHiA DDM™ analytics to go beyond initial response
Related genomic solutions
SOPHiA DDM™ for Solid Tumors
Benefit from advanced molecular profiling of solid tumors with our applications, from targeted to comprehensive genomics profiling
SOPHiA DDM™ for Hereditary Cancers
Confidently assess multiple types of challenging genetics variants associated with inherited cancers with our dedicated applications.
CE-IVD Oncology Applications by SOPHiA GENETICS™
Transform raw NGS data into actionable insights with our CE-marked in vitro diagnostic (IVD) applications.
Want to know more?
Get in touch with us.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. http://dx.doi.org/10.3322/caac.21660
2. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: Myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703–19. http://dx.doi.org/10.1038/s41375-022-01613-1